Prostate Cancer

"We look forward to announcing initial efficacy and safety data from the study, which we expect will be at the end of this quarter," says Salim Yazji, MD.

“We are hopeful that this therapy will help patients with prostate cancer and that this study will be just the first step towards the effective treatment of other bone tumors,” said Daniel Abate-Daga, PhD.

"In my view, at present in patients that have low-volume oligometastatic de novo metastatic prostate cancer, it's really an unknown whether comprehensive SBRT or other local therapy directed at oligomets improves survival," says Scott Morgan, MD, MSc, FRCPC.

“These findings suggest that guideline recommended treatment intensification remains low for patients with mCSPC in both Medicare and the Veterans Health Administration, but especially for Black patients,” says Daniel J. George, MD.

"Our clinical trial is the first to show a longer time to biochemical recurrence with chemotherapy plus standard hormone therapy for patients with locally advanced, high-risk prostate cancer," says Jiahua Pan, MD.

"In our analysis, the highest ranked treatment strategy was the combination of standard of care systemic therapy, an AR pathway inhibitor, and prostate radiotherapy," says Scott Morgan, MD, MSc, FRCPC.

"Participating in AUA guidelines is really an exciting time," says Todd M. Morgan, MD.

"The new results show that the 3-step method now used produces fewer insignificant cancer diagnoses than PSA screening,” says Anssi Auvinen, MD, PhD.

"There have been some pivotal clinical trials that have reported out, and they've really showed us that there is limited to maybe no role for adjuvant treatment after prostatectomy, and there is a huge role for early salvage treatment," says Todd M. Morgan, MD.

Data showed an increase in participant knowledge in 5 of the 10 items on the Prostate Cancer Knowledge Scale and a decrease in all 10 items on the Decisional Conflict Scale after watching the video.

"I think the main takeaway from this study is that prostate cancer is not as rare in trans women as we think it is, and that we really need to be giving this population the time that they deserve, and that they should be screened equally to their cis male counterparts," says Matthew Loria.

Drs Smith and Helfand look ahead and provide their thoughts on future directions in the treatment of patients with prostate cancer.

Focusing on metastatic prostate cancer, 2 experts have a comprehensive discussion on treatment options for patients with metastatic prostate cancer.

“Given that non-Hispanic Black men were 4 years younger than the non-Hispanic White men, these data suggest that microvascular dysfunction may appear earlier in non-Hispanic Black men following a prostate cancer diagnosis," says Abigayle B. Simon.

“The main takeaway is that we want to be working with [transgender and gender-diverse patients] the same way that we are working with cisgender folks,” says Matthew Loria.

The authors also project an 85% increase in the number of deaths from prostate cancer per year, which would bring the total number from 375,000 in 2020 to nearly 700,000 by 2040.

"I predict the future treatment for men with truly high-risk prostate cancer will see a fusion of what was thought to be standard local treatments combined with multimodality therapies that were initially impactful only in the more advanced disease state," writes Michael S. Cookson, MD, MMHC, FACS.

Among the patients who were on treatment for 12 weeks or less, treatment interruptions due to TEAEs occurred in 12.6% of patients, and discontinuations due to TEAEs occurred in 5.3% patients.

"We've been doing a lot of work at Johns Hopkins using high-dose testosterone therapies to treat patients with metastatic prostate cancer," says Mark C. Markowski, MD, PhD.

"We ultimately found that trans women from between the ages of 50 and 65 who were on hormone therapy had a 2.5-fold decreased risk of prostate cancer compared with cis men," says Matthew Loria.

The median radiographic progression-free survival with FG-3246 in mCRPC was 8.7 months.

"We hope that this paper encourages urologists to rethink non definitive treatment/active surveillance for prostate cancer and consider definitive treatment options earlier in the treatment pathway based on evidence that has accumulated," says Mital Patel, MD.

Matthew Smith, MD, PhD, and Brian T. Helfand, MD, discuss the treatment of patients with nonmetastatic castration-resistant prostate cancer.

Experts on prostate cancer discuss how treatment has evolved over the years, focusing on doublet and triplet therapy and their utility.

“I would just say that urologists should be focusing much more on the total amount of pattern 4, if they have that information available, than on the ratio of pattern 3 and 4, and therefore the grade group,” says Andrew J. Vickers, PhD.

"The point is healthy, adaptive changes that are sustainable, that you can keep off, because we don't want that rebound/regain," says Jill M. Hamilton-Reeves, PhD, RD, CSO.

“These results are encouraging and suggest that circulating biomarkers may be useful in guiding the use of radium-223 therapy,” says David T. Miyamoto, MD, PhD.

Comprehensive insights on ARPIs (androgen receptor pathway inhibitors) for the treatment of prostate cancer, highlighting what influences treatment decisions and safety profiles of the available APRIs.

Two prostate cancer experts discuss treatment decision-making practices for patients with newly diagnosed metastatic disease.

Overall, participating pathologists felt that there is potential to increase diagnostic efficiency by using Galen Prostate in a clinical setting.